key: cord-0920643-ri3if28g
authors: Gelderblom, H.; Gietema, J. A.; Desar, I.M.E.; Ajmone, N. M.; Jalving, M.; Kroep, J. R.; Nicolas, V.; Vaslin, A.; Tobal, K.; Purcea, D.; van Haren, S. F.; Damstrup, L.
title: First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours
date: 2020-09-30
journal: Annals of Oncology
DOI: 10.1016/j.annonc.2020.08.715
sha: 0f4e46a56cbd0623915c28e99611b6c44cb04161
doc_id: 920643
cord_uid: ri3if28g

nan

Oncology Dept., Churchill Hospital -Oxford University Hospitals NHS Foundation Trust, Oxford, UK Background: Nucleoside analogues form the backbone of systemic therapy for both solid and haematological malignancies. However, their clinical effectiveness is limited by cancer resistance mechanisms including transportation, intracellular activation and breakdown. NUC-7738 is a phosphoramidate transformation of 3'-deoxyadenosine (3'-dA, cordycepin), a derivative of adenosine that was first isolated from Cordyceps sinensis. The cytotoxic effect of 3'-dA is largely attributed to intracellular generation of the triphosphate metabolite, 3'-dATP, inhibiting DNA and RNA synthesis. Although 3'-dA has shown potent anti-tumour activity in non-clinical studies, it has not been successful in clinical studies due to its rapid breakdown by adenosine deaminase (ADA). With the addition of the phosphoramidate moiety, NUC-7738 can bypass the key resistance pathways associated with 3'-dA, including breakdown by ADA.

Trial design: NuTide:701 is a two-part, first-in-human phase I study in patients with advanced solid tumours who have exhausted all available treatment options.The primary objective is to determine the recommended Phase 2 dose (RP2D) and schedule of NUC-7738. Secondary objectives include safety, PK/PD and anti-tumour activity. Part 1, in patients with advanced solid tumours, will establish the RP2D and schedule of NUC-7738. Part 2 will further evaluate NUC-7738 in an expansion cohort of patients with advanced solid tumours or lymphoma. To date, 11 patients have been dosed in Part 1.

Legal entity responsible for the study: NuCana plc. Trial design: Methods This is a phase I, multi-center, open-label, dose escalation study of Debio 0123 as monotherapy (first cycle only) and in combination with CbPt, from cycle 2 in subjects with advanced solid tumors that recurred or progressed following prior platinum therapy. Primary objective: determination of the recommended phase II dose (RP2D) of Debio 0123 when administered in combination with CbPt using a modified Continual Reassessment Method (mCRM). Patients receive Debio 0123 orally once daily for the first 3 days of a 21 day-cycle as monotherapy during first cycle and in combination with CbPt in following cycles. Secondary objectives: includes determination of occurrence of dose-limiting toxicities (DLT) and characterization of the pharmacokinetics of Debio 0123 and its active metabolite, which are evaluated after single and repeated administration when administered alone or in combination with CbPt. Potential risk of QTc prolongation is evaluated by exposure-response modeling. Pharmacodynamics biomarkers including phospho-CDC2 are explored in pre-and post-treatment tumors and skin biopsies. Recruitment started in July 2019. Cohort 2 has been completed. Start of enrollment into cohort 3 is currently unknow due to COVID-19 but will begin as soon as possible.

Clinical trial identification: NCT03968653.

Legal entity responsible for the study: Debiopharm Interbational S.A. Trial design: This is the first-in-human, phase I, open-label, multicenter, dose-escalation study to investigate the safety, tolerability, PK, and clinical activity of NOV1601 in subjects with solid organ malignancies at four research-based hospitals in the Republic of Korea. The primary objective is to determine the recommended phase II dose (RP2D) of NOV1601 in adult subjects with solid organ malignancies. Dose escalation will follow a 3+3 design and will be based on prior cohort review. NOV1601 will be administered orally once daily (QD) or twice daily (BID) doses for continuous 28-day cycles. To date, 7 patients were enrolled and administered at 50mg QD or 100mg QD. NOV1601 is currently being administered at 150mg QD. The maximum tolerated dose (MTD) is not pre-determined yet. If MTD is not reached because of no dose-limiting toxicity, then the RP2D will be determined by PK and safety profiles. Efficacy per RECIST convention will be measured as an exploratory endpoint, and special attention will be cast to subjects with known genetic alterations involving NTRK family genes. Such cases will be validated at a central pathology laboratory using multiple diagnostic technologies available. Currently, this study is ongoing with affirmative PK and safety profiles as had been expected from nonclinical studies.

Clinical trial identification: NCT04014257. 

Background: The pan-FGFR tyrosine kinase inhibitor erdafitinib is approved by the US Food and Drug Administration for adults with locally advanced or metastatic urothelial carcinoma and susceptible FGFR3/2 alterations who have progressed during or after 1 line of platinum-containing chemotherapy. FGFR alterations are potential oncogenic drivers that have been reported in many solid tumours in adult and pediatric pts. Because of limited response to standard of care options in patients failing systemic therapy

BPC, n ¼ 240; EC, n ¼ 40) will be enrolled. The primary efficacy end point is overall response rate (ORR) per Independent Review Committee. Secondary end points include investigator-assessed ORR, duration of response, disease control rate, progression-free survival, overall survival, safety, pharmacokinetics, and health-related quality of life. Safety assessments include adverse events, vital signs, electrocardiograms, physical examinations, laboratory tests, performance status assessment, growth assessments in adolescents, and ophthalmologic examination

Research grant/Funding (institution): Mirati Therapeutics; Research grant/Funding (institution): Novartis. O. Witt: Full/Part-time employment: DKFZ Germany